Pharmacogenetics of pain and analgesia

Clinical Genetics

Volumn 82, Issue 4, 2012, Pages 321-330

  Smith, Mt ^a   Muralidharan, A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Analgesia; Environment; Epigenetics; Genetic association studies; Genetics; Inter individual variability; Pain; SNP

Indexed keywords

ALFENTANIL; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CATECHOL METHYLTRANSFERASE; CODEINE; DEXTROMETHORPHAN; DIHYDROCODEINE; FENTANYL; GABAPENTIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HYDROMORPHONE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; OXYMORPHONE; POTASSIUM CHANNEL KV9.1; PREGABALIN; PURINERGIC P2X7 RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SODIUM CHANNEL NAV1.7; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ADJUVANT THERAPY; ANALGESIA; ANTINOCICEPTION; CHRONIC PAIN; COMT GENE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPIGENETICS; GCH1 GENE; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HERITABILITY; HUMAN; INFLAMMATORY PAIN; KCNS1 GENE; MAOA GENE; MAOB GENE; NET GENE; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OPRM1 GENE; P2RX7 GENE; PAIN; PAIN ASSESSMENT; PHARMACOGENETICS; PHENOTYPE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RECEPTOR GENE; REVIEW; SCN9A GENE; SERT GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TWINS;

ANALGESICS; ANIMALS; EPIGENESIS, GENETIC; GENETIC ASSOCIATION STUDIES; HUMANS; INDIVIDUALITY; ION CHANNELS; MICE; NEUROTRANSMITTER AGENTS; PAIN; PHARMACOGENETICS; RATS;

RODENTIA;

EID: 84866173610     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2012.01936.x     Document Type: Review

References (134)

1. Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg 2007: 105: 205-221.
2. Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med 2010: 16: 1241-1247.
3. Coghill RC, McHaffie JG, Yen YF. Neural correlates of interindividual differences in the subjective experience of pain. Proc Natl Acad Sci U S A 2003: 100: 8538-8542.
4. Muralidharan A, Smith MT. Pain, analgesia and genetics. J Pharm Pharmacol 2011: 63: 1387-1400.
5. Kleine-Brueggeney M, Musshoff F, Stuber F et al. Pharmacogenetics in palliative care. Forensic Sci Int 2010: 203: 63-70.
6. Lacroix-Fralish ML, Mogil JS. Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol 2009: 49: 97-121.
7. Lotsch J, Geisslinger G, Tegeder I. Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther 2009: 124: 168-184.
8. Kim H, Clark D, Dionne RA. Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain 2009: 10: 663-693.
9. Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011: 152: 1139-1145.
10. Mogil JS, Wilson SG, Bon K et al. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 1999: 80: 67-82.
11. Mogil JS, Wilson SG, Bon K et al. Heritability of nociception II. 'Types' of nociception revealed by genetic correlation analysis. Pain 1999: 80: 83-93.
12. Lariviere WR, Wilson SG, Laughlin TM et al. Heritability of nociception. III. Genetic relationships among commonly used assays of nociception and hypersensitivity. Pain 2002: 97: 75-86.
13. Smith SB, Crager SE, Mogil JS. Paclitaxel-induced neuropathic hypersensitivity in mice: responses in 10 inbred mouse strains. Life Sci 2004: 74: 2593-2604.
14. Rode F, Thomsen M, Brolos T et al. The importance of genetic background on pain behaviours and pharmacological sensitivity in the rat spared serve injury model of peripheral neuropathic pain. Eur J Pharmacol 2007: 564: 103-111.
15. Mogil JS, Kest B, Sadowski B et al. Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay. J Pharmacol Exp Ther 1996: 276: 532-544.
16. Chesler EJ, Ritchie J, Kokayeff A et al. Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 2003: 106: 325-335.
17. Lacroix-Fralish ML, Ledoux JB, Mogil JS. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. Pain 2007: 131: 3 e1-4.
18. Crabbe JC, Wahlsten D, Dudek BC. Genetics of mouse behavior: interactions with laboratory environment. Science 1999: 284: 1670-1672.
19. Lewejohann L, Reinhard C, Schrewe A et al. Environmental bias? Effects of housing conditions, laboratory environment and experimenter on behavioral tests. Genes Brain Behav 2006: 5: 64-72.
20. Chesler EJ, Wilson SG, Lariviere WR et al. Influences of laboratory environment on behavior. Nat Neurosci 2002: 5: 1101-1102.
21. Wahlsten D, Metten P, Phillips TJ et al. Different data from different labs: lessons from studies of gene-environment interaction. J Neurobiol 2003: 54: 283-311.
22. Lariviere WR, Mogil JS. The genetics of pain and analgesia in laboratory animals. Methods Mol Biol 2010: 617: 261-278.
23. Mogil JS, Bailey AL. Sex and gender differences in pain and analgesia. Prog Brain Res 2010: 186: 141-157.
24. Williams FM, Spector TD, MacGregor AJ. Pain reporting at different body sites is explained by a single underlying genetic factor. Rheumatology (Oxford) 2010: 49: 1753-1755.
25. Livshits G, Popham M, Malkin I et al. Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study. Ann Rheum Dis 2011: 70: 1740-1745.
26. Hartvigsen J, Nielsen J, Kyvik KO et al. Heritability of spinal pain and consequences of spinal pain: a comprehensive genetic epidemiologic analysis using a population-based sample of 15, 328 twins ages 20-71 years. Arthritis Rheum 2009: 61: 1343-1351.
27. Norbury TA, MacGregor AJ, Urwin J et al. Heritability of responses to painful stimuli in women: a classical twin study. Brain 2007: 130: 3041-3049.
28. Nielsen CS, Stubhaug A, Price DD et al. Individual differences in pain sensitivity: genetic and environmental contributions. Pain 2008: 136: 21-29.
29. Angst MS, Phillips NG, Drover DR et al. Pain sensitivity and opioid analgesia: A pharmacogenomic twin study. Pain 2012: 153: 1397-1409.
30. Xu B, Descalzi G, Ye HR et al. Translational investigation and treatment of neuropathic pain. Mol Pain 2012: 8: 15.
31. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010: 26 (Suppl. 10): S16-S20.
32. Shabalina SA, Zaykin DV, Gris P et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009: 18: 1037-1051.
33. Janicki PK, Schuler G, Francis D et al. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg 2006: 103: 1011-1017.
34. Fillingim RB, Kaplan L, Staud R et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005: 6: 159-167.
35. Campa D, Gioia A, Tomei A et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008: 83: 559-566.
36. Chou WY, Wang CH, Liu PH et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006: 105: 334-337.
37. Chou WY, Yang LC, Lu HF et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006: 50: 787-792.
38. Reyes-Gibby CC, Shete S, Rakvag T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007: 130: 25-30.
39. Sia AT, Lim Y, Lim EC et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008: 109: 520-526.
40. Oertel BG, Schmidt R, Schneider A et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics 2006: 16: 625-636.
41. Klepstad P, Rakvag TT, Kaasa S et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004: 48: 1232-1239.
42. Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 2009: 146: 270-275.
43. Rosenbaum T, Simon SA, Islas LD. Ion channels in analgesia research. Methods Mol Biol 2010: 617: 223-236.
44. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 2005: 57: 397-409.
45. Ocana M, Cendan CM, Cobos EJ et al. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004: 500: 203-219.
46. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain 2006: 7: S3-S12.
47. Toledo-Aral JJ, Moss BL, He ZJ et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci U S A 1997: 94: 1527-1532.
48. Nassar MA, Stirling LC, Forlani G et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci U S A 2004: 101: 12706-12711.
49. Nassar MA, Levato A, Stirling LC et al. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain 2005: 1: 24.
50. Cox JJ, Sheynin J, Shorer Z et al. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations. Hum Mutat 2010: 31: E1670-E1686.
51. Reimann F, Cox JJ, Belfer I et al. Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A 2010: 107: 5148-5153.
52. Valdes AM, Arden NK, Vaughn FL et al. Role of the Nav1.7 R1150W amino acid change in susceptibility to symptomatic knee osteoarthritis and multiple regional pain. Arthritis Care Res (Hoboken) 2011: 63: 440-444.
53. Costigan M, Belfer I, Griffin RS et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain 2010: 133: 2519-2527.
54. Salinas M, Duprat F, Heurteaux C et al. New modulatory alpha subunits for mammalian Shab K+ channels. J Biol Chem 1997: 272: 24371-24379.
55. Shepard AR, Rae JL. Electrically silent potassium channel subunits from human lens epithelium. Am J Physiol 1999: 277: C412-C424.
56. Stocker M, Hellwig M, Kerschensteiner D. Subunit assembly and domain analysis of electrically silent K+ channel alpha-subunits of the rat Kv9 subfamily. J Neurochem 1999: 72: 1725-1734.
57. Chessell IP, Hatcher JP, Bountra C et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005: 114: 386-396.
58. Trang T, Beggs S, Salter MW. ATP receptors gate microglia signaling in neuropathic pain. Exp Neurol 2012: 234: 354-361.
59. Sorge RE, Trang T, Dorfman R et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 2012: 18: 595-599.
60. Fuller SJ, Stokes L, Skarratt KK et al. Genetics of the P2X7 receptor and human disease. Purinergic Signal 2009: 5: 257-262.
61. Jarvis MF, Boyce-Rustay JM. Neuropathic pain: models and mechanisms. Curr Pharm Des 2009: 15: 1711-1716.
62. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry 2010: 81: 1372-1373.
63. Kim H, Lee H, Rowan J et al. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2006: 2: 24.
64. Gentile G, Borro M, Simmaco M et al. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug Metab Toxicol 2011: 7: 39-47.
65. Schurks M, Rist PM, Kurth T. 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia 2010: 30: 1296-1305.
66. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics 2007: 8: 67-74.
67. Park JW, Kim JS, Kim YI et al. Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache 2005: 45: 1229-1235.
68. Lindstedt F, Lonsdorf TB, Schalling M et al. Perception of thermal pain and the thermal grill illusion is associated with polymorphisms in the serotonin transporter gene. PLoS One 2011: 6: e17752.
69. Lindstedt F, Berrebi J, Greayer E et al. Conditioned pain modulation is associated with common polymorphisms in the serotonin transporter gene. PLoS One 2011: 6: e18252.
70. Schurks M, Rist PM, Kurth T. STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses. J Headache Pain 2010: 11: 317-326.
71. Costigan M, Befort K, Karchewski L et al. Replicate high-density rat genome oligonucleotide microarrays reveal hundreds of regulated genes in the dorsal root ganglion after peripheral nerve injury. BMC Neurosci 2002: 3: 16.
72. Tegeder I, Costigan M, Griffin RS et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006: 12: 1269-1277.
73. Kim H, Dionne RA. Lack of influence of GTP cyclohydrolase gene (GCH1) variations on pain sensitivity in humans. Mol Pain 2007: 3: 6.
74. Tegeder I, Adolph J, Schmidt H et al. Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain 2008: 12: 1069-1077.
75. Antoniades C, Shirodaria C, Van Assche T et al. GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol 2008: 52: 158-165.
76. Zhang L, Rao F, Zhang K et al. Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk. J Clin Invest 2007: 117: 2658-2671.
77. Lotsch J, Klepstad P, Doehring A et al. A GTP cyclohydrolase 1 genetic variant delays cancer pain. Pain 2010: 148: 103-106.
78. Gursoy S, Erdal E, Herken H et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003: 23: 104-107.
79. Emin Erdal M, Herken H, Yilmaz M et al. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res 2001: 94: 193-196.
80. Diatchenko L, Slade GD, Nackley AG et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005: 14: 135-143.
81. Kim H, Neubert JK, San Miguel A et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004: 109: 488-496.
82. Hagen K, Pettersen E, Stovner LJ et al. The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J Headache Pain 2006: 7: 70-74.
83. Birklein F, Depmeier C, Rolke R et al. A family-based investigation of cold pain tolerance. Pain 2008: 138: 111-118.
84. Hocking LJ, Smith BH, Jones GT et al. Genetic variation in the beta2-adrenergic receptor but not catecholamine-O-methyltransferase predisposes to chronic pain: results from the 1958 British Birth Cohort Study. Pain 2010: 149: 143-151.
85. Rakvag TT, Klepstad P, Baar C et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005: 116: 73-78.
86. Sery O, Hrazdilova O, Didden W et al. The association of monoamine oxidase B functional polymorphism with postoperative pain intensity. Neuro Endocrinol Lett 2006: 27: 333-337.
87. Zammit S, Jones G, Jones SJ et al. Polymorphisms in the MAOA, MAOB, and COMT genes and aggressive behavior in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004: 128B: 19-20.
88. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998: 103: 273-279.
89. Gentile G, Borro M, Lala N et al. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010: 11: 431-435.
90. Corominas R, Sobrido MJ, Ribases M et al. Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2010: 153B: 177-184.
91. Filic V, Vladic A, Stefulj J et al. Monoamine oxidases A and B gene polymorphisms in migraine patients. J Neurol Sci 2005: 228: 149-153.
92. Gentile G, Missori S, Borro M et al. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010: 11: 151-156.
93. Smith MT, Muralidharan A. Pharmacogenetics. Pain: Clinical Updates 2010: XVIII: 1-8.
94. Rollason V, Samer C, Piguet V et al. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics 2008: 9: 905-933.
95. Ingelman-Sundberg M, Sim SC, Gomez A et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007: 116: 496-526.
96. Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010: 11: 843-864.
97. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002: 360: 1155-1162.
98. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009: 48: 689-723.
99. Shimada T, Yamazaki H, Mimura M et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270: 414-423.
100. Sistonen J, Sajantila A, Lao O et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007: 17: 93-101.
101. Dalen P, Frengell C, Dahl ML et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997: 19: 543-544.
102. Gasche Y, Daali Y, Fathi M et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004: 351: 2827-2831.
103. VanderVaart S, Berger H, Sistonen J et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit 2011: 33: 425-432.
104. Koren G, Cairns J, Chitayat D et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006: 368: 704.
105. Madadi P, Koren G, Cairns J et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007: 53: 33-35.
106. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatr Anaesth 2007: 17: 684-687.
107. de Wildt SN, Koren G. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected]. Paediatr Anaesth 2008: 18: 273-274 author reply 275-276.
108. Stamer UM, Stuber F. Codeine induced respiratory depression in a child. Paediatr Anaesth 2008: 18: 272-273 author reply 275-276.
109. Poulsen L, Arendt-Nielsen L, Brosen K et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996: 60: 636-644.
110. Subrahmanyam V, Renwick AB, Walters DG et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001: 29: 1146-1155.
111. Stamer UM, Lehnen K, Hothker F et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003: 105: 231-238.
112. Stamer UM, Musshoff F, Kobilay M et al. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007: 82: 41-47.
113. Kirchheiner J, Keulen JT, Bauer S et al. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008: 28: 78-83.
114. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005: 6: 357-371.
115. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997: 32: 210-258.
116. Hu YF, He J, Chen GL et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005: 353: 187-192.
117. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000: 67: 48-56.
118. Lamba JK, Lin YS, Thummel K et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002: 12: 121-132.
119. Liu CH, Peck K, Huang JD et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005: 6: 731-747.
120. Ruzilawati AB, Suhaimi AW, Gan SH. Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects. Clin Chim Acta 2007: 383: 158-162.
121. Gourlay GK, Kowalski SR, Plummer JL et al. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988: 67: 329-337.
122. Zhang W, Chang YZ, Kan QC et al. CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 2010: 66: 61-66.
123. Dong ZL, Li H, Chen QX et al. Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population. J Clin Pharm Ther 2011: 37: 153-156.
124. Yuan R, Zhang X, Deng Q et al. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta 2011: 412: 755-760.
125. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000: 40: 581-616.
126. Coffman BL, Rios GR, King CD et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997: 25: 1-4.
127. King C, Tang W, Ngui J et al. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001: 61: 49-53.
128. Holthe M, Rakvag TN, Klepstad P et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003: 3: 17-26.
129. Denk F, McMahon SB. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron 2012: 73: 435-444.
130. LaCroix-Fralish ML, Austin JS, Zheng FY et al. Patterns of pain: meta-analysis of microarray studies of pain. Pain 2011: 152: 1888-1898.
131. Hwang CK, Song KY, Kim CS et al. Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters. Mol Cell Biol 2007: 27: 4720-4736.
132. Lin YC, Flock KE, Cook RJ et al. Effects of trichostatin A on neuronal mu-opioid receptor gene expression. Brain Res 2008: 1246: 1-10.
133. Nielsen DA, Yuferov V, Hamon S et al. Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. Neuropsychopharmacology 2009: 34: 867-873.
134. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 2006: 7: 181.